The in-vitro activity and beta-lactamase stability of carumonam.
Carumonam is a monobactam with a beta-carbamyloxmethyl group at position 4. It inhibited 90% of Enterobacteriaceae at less than or equal to 8 mg/l and had in-vitro activity similar to that of cefotaxime, ceftazidime and aztreonam. Fifty per cent of Enterobacter, Citrobacter and Serratia isolates were inhibited by 4 mg/l, but isolates resistant to aztreonam and ceftazidime were not inhibited. Carumonam, like aztreonam, did not inhibit Gram-positive or anaerobic species. Carumonam was not destroyed by the common plasmid- and chromosomally-mediated beta-lactamases and was more stable than aztreonam to attack by the K-1 beta-lactamase of Klebsiella oxytoca. Carumonam inhibited Richmond-Sykes type Ia and Id beta-lactamases but was a poor inhibitor of type III enzymes. It did not induce beta-lactamases.
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D001398:Aztreonam / Q000494:pharmacology / Q000031:analogs & derivatives; D002439:Cefotaxime / Q000494:pharmacology; D002442:Ceftazidime / Q000494:pharmacology; D003470:Culture Media; D006088:Gram-Negative Aerobic Bacteria / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D010878:Piperacillin / Q000494:pharmacology; D014031:Tobramycin / Q000494:pharmacology; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D003470:Culture Media; D065093:beta-Lactamase Inhibitors; C044145:carumonam; D002442:Ceftazidime; D001618:beta-Lactamases; D001398:Aztreonam; D002439:Cefotaxime; D014031:Tobramycin; D010878:Piperacillin